Drug Profile

Deucravacitinib - Bristol-Myers Squibb

Alternative Names: BMS-986165; BMS-986165-01; Sotyktu

Latest Information Update: 21 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Class Amides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles; Urologics
Mechanism of Action TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Plaque psoriasis
Registered Erythrodermic psoriasis; Pustular psoriasis
Preregistration Psoriatic arthritis
Phase III Juvenile rheumatoid arthritis; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus
Phase II Alopecia areata; Crohn's disease; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Hidradenitis suppurativa; Lupus nephritis; Ulcerative colitis
No development reported Inflammatory bowel diseases

14 Aug 2025 Bristol-Myers Squibb plans a phase III PRAGMATYK trial for Plaque psoriasis (In adults, In elderly) in USA, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, South Korea, Mexico, Poland, Puerto Rico, Romania, Spain, Sweden, Taiwan, United Kingdom (PO) in October 2025 (NCT07116967)
22 Jul 2025 Preregistration for Psoriatic arthritis (Treatment-naive) in USA (PO)
22 Jul 2025 Preregistration for Psoriatic arthritis in China (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com